Corrigendum to 'Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein' [Pharmacol. Res. 175 (2022) 105975]

Affiliations

• ¹ Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy; Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., Dokki, 12622 Giza, Egypt.
• ² Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy.
• ³ Pharmacognosy Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., Dokki, 12622 Giza, Egypt.
• ⁴ Chemistry of Medicinal Plants Department & Biology Unit of Central Laboratory, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., Dokki, 12622 Giza, Egypt.
• ⁵ Zoology Department, Faculty of Science, Cairo University, Gamaa Street, Giza, Egypt.
• ⁶ Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 El Bohouth St., Dokki, 12622 Giza, Egypt.
• ⁷ Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy. Electronic address: chiara.riganti@unito.it.